On June 17, 2014, the U.S. Food and Drug Administration (FDA) issued two draft guidance documents that address issues relating to manufacturer communications over internet and social media platforms. Through these long-awaited draft guidance documents, the FDA seeks to provide more clarity regarding its views on the permissible ways in which drug and medical device firms may discuss their marketed products and provide corrections to independent third-party communications about their products through these platforms. This On the Subject provides an overview of these new draft guidance documents and their implications for drug and device companies.
Please click here to read the full article.
